

## **Disclosure of Transfers of Value Methodology Note for Diurnal 2016**

Diurnal is a small research based company. During 2016 there were no marketed products so non-research and development activities were limited to an advisory board and one research and one educational grant- one of which was to a patient group organization and is declared separately below. Diurnal had three active product development programmes. Transfers of value relating to these three programmes were recorded and consolidated at year end. The total spend was discussed and validated at a company management meeting with membership including the heads of medical, finance, commercial and clinical operations functions. The aggregated total is declared on the accompanying spread sheet.

In calculating the aggregated total the following methodologies have been used.

- Amounts declared do not include VAT due to the differing levels of VAT across the areas where Diurnal has clinical trials programmes ongoing.
- Amounts declared are in UK sterling with the conversion rates at the time being applied
- All payments worldwide are declared as Diurnal is headquartered in the UK
- Where contracts extend beyond a single year, in year payments only are declared.
- Diurnal does not have any over the counter business or medical device business
- In including worldwide payments, Diurnal goes beyond the requirements of the EFPIA and ABPI codes and the US legislation.
- Individual consent has been sought for individual payments to Healthcare professionals with no refusals.
- Diurnal has made no non-monetary transfers of value in 2016
- Diurnal has not worked with any other pharmaceutical companies in 2016.

Unrestricted Educational Grant to CARES Patient Support Organisation £18880

Charitable Donation to CARES Foundation Patient Support Organisation £8185

